PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Inclusion Criteria

- Patients must have a biopsy-proven diagnosis of high risk, very high risk, or locally
advanced prostate cancer

- Patients must have a diagnosis of high risk, very high risk, or locally advanced
prostate cancer per NCCN Guidelines (T3-T4 disease)

- Patients are healthy enough to be deemed surgical candidates with an ECOG performance
status of 0-2

- Patients must be age ≥ 18 years

- Patients must agree to use adequate contraception (e.g. barrier method of birth
control; abstinence) prior to study entry, for the duration of study participation,
and for 30 days following completion of the imaging

- Patients must have the ability to understand and the willingness to sign a written
informed consent prior to registration on study

Exclusion Criteria

- Patients who have contraindications to MRI (i.e. pacemakers, aneurysm clips or shaped
fragments)

- Patients who are claustrophobic will be required to take an anti-anxiety medication
prescribed by their physician one hour prior to the scan

- Patients may not be receiving any other treatments or investigational agents

- Patients with a GFR <30mL/min are ineligible to receive intravenous contrast per
standard MR exclusion criteria

- Patients not interested in pursuing surgical intervention for their disease (i.e.
refusing treatment or requesting radiation oncology referral)

- Patients who have received androgen deprivation therapy or prior surgery for prostate
cancer

- Patients who report taking multivitamins and/or folate supplements on the day of the
scan